110 related articles for article (PubMed ID: 8208973)
1. Salivary gland tumors: pretherapy evaluation with PET.
Keyes JW; Harkness BA; Greven KM; Williams DW; Watson NE; McGuirt WF
Radiology; 1994 Jul; 192(1):99-102. PubMed ID: 8208973
[TBL] [Abstract][Full Text] [Related]
2. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
3. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
4. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
5. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions].
Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M
Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472
[TBL] [Abstract][Full Text] [Related]
6. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
7. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR
Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions.
Okamura T; Kawabe J; Koyama K; Ochi H; Yamada R; Sakamoto H; Matsuda M; Ohashi Y; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():209-13. PubMed ID: 9879423
[TBL] [Abstract][Full Text] [Related]
10. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors.
Uchida Y; Minoshima S; Kawata T; Motoori K; Nakano K; Kazama T; Uno T; Okamoto Y; Ito H
Clin Nucl Med; 2005 Mar; 30(3):170-6. PubMed ID: 15722820
[TBL] [Abstract][Full Text] [Related]
12. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.
Griffeth LK; Dehdashti F; McGuire AH; McGuire DJ; Perry DJ; Moerlein SM; Siegel BA
Radiology; 1992 Jan; 182(1):185-94. PubMed ID: 1727280
[TBL] [Abstract][Full Text] [Related]
13. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
15. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
17. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET Imaging of Salivary Gland Tumors.
Larson CR; Wiggins RH
Semin Ultrasound CT MR; 2019 Oct; 40(5):391-399. PubMed ID: 31635766
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
Mori T; Nomori H; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Oncol; 2008 Apr; 3(4):358-64. PubMed ID: 18379353
[TBL] [Abstract][Full Text] [Related]
20. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
Patz EF; Lowe VJ; Hoffman JM; Paine SS; Burrowes P; Coleman RE; Goodman PC
Radiology; 1993 Aug; 188(2):487-90. PubMed ID: 8327702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
